Kalp yetersizliği olan hastalarda galektin-3'ün değerlendirilmesi ve NT-proBNP düzeyleri ile ilişkisi: Vaka-kontrol çalışması

Öz

Amaç: Kardiyak fibroz kardiyak remodelingde patolojik bir durumdur ve kalp hastalıkları ile ilişkilidir. Bu çalışmanın amacı galaktin-3'ün kalp yetmezliği (KY) olan hastalarda N-terminal pro B tipi natriüretik peptid (NT-pro-BNP) düzeyleri ile ilişkisini araştırmaktır.
Yöntemler: Çalışmaya KY tanısı olan toplam 50 hasta (hasta grubu) ve ejeksiyon fraksiyonu normal olan 30 birey (kontrol grubu) dahil edildi. Tüm bireylerde serum galektin‐3 ve plazma NT-pro-BNP düzeyleri ölçüldü. Bireylerin demografik ve klinik özellikleri kaydedildi. Galaktin-3 ve NT-pro-BNP düzeyleri gruplar arasında karşılaştırıldı.
Bulgular: KY olan hastalarda galaktin-3 ve NT-pro-BNP düzeyleri kontrol grubundan (37.5 (18.0-80.0), 12.0 (8.0-14.0), P<0.001; 467.0 (1157.5-5107.2), 50.0 (35.0-102.0) P<0.001, sırasıyla) anlamlı derecede yüksek bulundu.. Galaktin-3, KY hastalarında serum glukoz, kreatin, sol atriyal çap, ejeksiyon fraksiyonu ve NT-pro-BNP düzeyleri ile korele olarak bulundu. NT-pro-BNP ve Galaktin-3 düzeyleri arasında pozitif ve anlamlı bir ilişki vardı (r=0.742 P=0.001). Ayrıca, ejeksiyon fraksiyonu ile Galaktin-3 seviyeleri arasında negatif ve anlamlı bir korelasyon vardı (r=-0.556, P=0.001).
Sonuç: Sonuç olarak, bu çalışma, sistolik HF hastalarında galektin-3 ve NT-pro-BNP düzeylerinin anlamlı şekilde daha yüksek olduğunu göstermektedir. Galektin-3, NT-pro-BNP ile pozitif ve anlamlı, ejeksiyon fraksiyonu ile negatif korelasyon gösterdi.

Anahtar Kelimeler

• Galaktin-3,NT-pro-BNP,NT-pro-BNP,Kalp yetmezliği,Ejeksiyon fraksiyonu

Evaluation of galectin-3 in patients with heart failure and its relationship with NT-proBNP levels: A case-control study

Öz

Background: Cardiac fibrosis is a pathological phenomenon in cardiac remodelling and it is associated with heart diseases. The aim of this study was to investigate the relationship of galactin-3 with N-terminal pro B-type natriuretic peptide (NT-pro-BNP) levels in patients with heart failure (HF). Material and Method: A total of 50 patients with HF and 30 patients with normal ejection fraction were enrolled into this study. Serum galectin‐3 levels and plasma NT-pro-BNP were measured in all subjects. Demographic and clinical characteristics of the patients were recorded. The galactin-3 and NT-pro-BNP levels were compared between the groups. Results: Patients with HF had significantly higher galactin-3 and NT-pro-BNP levels than control patients (37.50 (18.00-80.00) versus 12.00 (8.00-14.00), P<0.001; 467.00 (1157.50-5107.25) versus 50.00 (35.00-102.00) P<0.001, respectively). galactin-3 was correlated with serum glucose, creatine, left atrial diameter, ejection fraction and NT-pro-BNP in the HF patients. There was a positive and significant correlation between the NT-pro-BNP and Galactine-3 levels (r=0.742 P=0.001). In addition, there was an inverse and significant correlation between the ejection fraction and Galactine-3 levels (r=-0.556 P=0.001). Conclusion: This study demonstrated an association between galactin-3 and NT-pro-BNP levels. We found that galactin-3 and NT-pro-BNP levels was significantly higher in patients with HF. Our study also showed that galactin-3 was strongly correlated with NT-pro-BNP levels.

Anahtar Kelimeler

• Galectin-3,NT-pro-BNP,Heart failure,Ejection fraction

Kaynakça

1. 1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30.
2. 2. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, et al. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 1999;59(24):6239–45.
3. 3. Hughes R. The galectin family of mammalian carbohydrate-binding molecules. 1997;
4. 4. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–8.
5. 5. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta BBA-Gen Subj. 2006;1760(4):616–35.
6. 6. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J. 2002;19(7–9):527–35.
7. 7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.
8. 8. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6(2):219–26.

9. 9. Clementy N, Benhenda N, Piver E, Pierre B, Bernard A, Fauchier L, et al. Serum galectin-3 levels predict recurrences after ablation of atrial fibrillation. Sci Rep. 2016;6:34357.
10. 10. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–8.
11. 11. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358(20):2148–59.
12. 12. Vasile VC, Jaffe AS. Natriuretic peptides and analytical barriers. Clin Chem. 2017;63(1):50–8.
13. 13. García-Alvarez A, Regueiro A, Hernández J, Kasa G, Sitges M, Bosch X, et al. Additional value of B-type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST-segment elevation acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2014;3(2):132–40.
14. 14. Karabağ Y, Rencuzogullari I, Çağdaş M, Karakoyun S, Yesin M, Uluganyan M, et al. Association between BNP levels and new-onset atrial fibrillation. Herz. 2018;43(6):548–54.
15. 15. Lam CS, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39(20):1770–80.
16. 16. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2011;33(16):2001–6.
17. 17. Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12(1):2.
18. 18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560–72.
19. 19. National CEPN. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143.
20. 20. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care. 2006 Aug;29(8):1955–62.
21. 21. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2(5):358–67.
22. 22. Otto CM. Textbook of Clinical Echocardiography E-Book. Elsevier Health Sciences; 2013.
23. 23. Song X, Qian X, Shen M, Jiang R, Wagner MB, Ding G, et al. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta BBA-Mol Cell Res. 2015;1853(2):513–21.
24. 24. van der Velde AR, Lexis CP, Meijers WC, van der Horst IC, Lipsic E, Dokter MM, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2016;452:50–7.
25. 25. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7(1):1–8.
26. 26. Lisowska A, Knapp M, Tycińska A, Motybel E, Kamiński K, Święcki P, et al. Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis. 2016;246:309–17.
27. 27. Chow SL, Maisel AS, Anand I, Bozkurt B, De Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054–91.
28. 28. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.
29. 29. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61(14):1498–506.
30. 30. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52(8):1528–38.
31. 31. Linssen GCM, Jaarsma T, Hillege HL, Voors AA, van Veldhuisen DJ. A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure. Neth Heart J. 2018;26(10):486–92.
32. 32. Barman HA, Durmaz E, Atici A, Kahyaoglu S, Asoglu R, Sahin I, et al. The relationship between galectin-3 levels and fragmented QRS (fQRS) in patients with heart failure with reduced left ventricular ejection fraction. Ann Noninvasive Electrocardiol. 2019;e12671.